Please try another search
Case reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed patients who have relapsing babesiosis and...
MILWAUKEE--(BUSINESS WIRE)--Sensient Technologies Corporation (NYSE: SXT) will hold its earnings call and webcast to discuss 2024 third quarter results at 8:30 a.m. CDT on Friday, October 25,...
MILWAUKEE--(BUSINESS WIRE)--Sensient Technologies Corporation (NYSE: SXT) will hold its earnings call and webcast to discuss 2024 second quarter results at 8:30 a.m. CDT on Friday, July 26, 2024....
Sensient Technologies (SXT) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.89 per share a year ago. These...
Sensient Technologies (SXT) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.89 per share a year ago. These...
Sensient Technologies (SXT) came out with quarterly earnings of $0.75 per share, missing the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.95 per share a year ago. These...
Instrument Type
Region
Sector
Industry
Date
Category
Provider